With all due respect, this is the third message to request a broader base of discussion regarding JNJ. There is no monopoly on this board to open a dialogue. If you have questions or comments regarding JNJ's other products, its stock, or whatever, please open the dialogue. If anyone is interested, they will respond. It seems silly to expect some level of equal reporting or dialogue. Without being disrespectful, my interest in JNJ is rooted in how they will respond to a crisis that msut be udnerway in their cardiology division. As we speak, AVE just received FDA approval for two of their stents today! While it's been previously commented on, thismay or may not have an impact on JNJ's stock price. It clearly has major ramifications for some very high profile stocks; i.e., MDT, BSX, GDT, USS, BCR, etc. It may also set in motion the need for JNJ and/or others to acquire additional companies. If you're on this board because you are an investor, it's hard to focus on the balance of JNJ, whichis obviously a very good company.